CANNABIDEX

Welcome to the Brand page for “CANNABIDEX”, which is offered here for Pharmaceutical and veterinary preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for use in the treatment of dravet syndrome and lennox-gestaut syndrome; pharmaceutical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of dravet syndrome and lennox-gestaut syndrome; pharmaceutical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of dravet syndrome and lennox-gestaut syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for use in the treatment of dravet syndrome and lennox-gestaut syndrome; medicinal herbs, medicinal oils, pure extracts of medicinal plants and herbs for pharmaceutical use, dietetic foodstuffs specially adapted for medicinal purposes, herb teas for medicinal purposes, none of the foregoing herbs, oils, extracts, foodstuffs, or teas comprised of cannabis sativa l or any oils, extracts, ingredients or derivatives thereof with a delta-9 tetrahydrocannabinol (thc) concentration of more than 0.3 percent on a dry weight basis;.

Its status is currently believed to be active. Its class is unavailable. “CANNABIDEX” is believed to be currently owned by “GW Research Limited”.